

Editor

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Caroline Ospelt
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2023 BMJ Publishing Group Ltd and European Alliance of Associations for Rheumatology. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Review

- 585** Novel aspects in the pathophysiology and diagnosis of glomerular diseases
A Kronbichler, I Bajema, D Geetha, M Säemann

Viewpoint

- 594** Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022
K L Winthrop, J D Isaacs, P J Mease, D T Boumpas, X Baraliakos, J-E Gottenberg, S Siebert, M Mosca, N Basu, D Orange, R Lories, D Aletaha, I B McInnes, T W J Huizinga, R E Voll, E M Gravallese, F C Breedveld, J S Smolen

Heroes and pillars of rheumatology

- 599** Tsai-Fan Yu: physician and researcher who established modern gout management
N Dalbeth

Rheumatoid arthritis

- 601** Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme
T Frisell, H Bower, M Morin, E Baecklund, D Di Giuseppe, B Delcoigne, N Feltelius, H Forsblad-d'Elia, E Lindqvist, U Lindström, J Askeling, on behalf of the ARTIS Study group

- 611** Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis
S L Smith, S Alexander, N Nair, S Viatte, S Eyre, K L Hyrich, A W Morgan, A G Wilson, J D Isaacs, D Plant, A Barton

- 621** Genomic repertoires linked with pathogenic potency of arthritogenic *Prevotella copri* isolated from the gut of patients with rheumatoid arthritis
T Nii, Y Maeda, D Motooka, M Naito, Y Matsumoto, T Ogawa, E Oguro-Igashira, T Kishikawa, M Yamashita, S Koizumi, T Kurakawa, R Okumura, H Kayama, M Murakami, T Sakaguchi, B Das, S Nakamura, Y Okada, A Kumanogoh, K Takeda

- 630** Neutrophil extracellular trap-associated carbamylation and histones trigger osteoclast formation in rheumatoid arthritis
L J O'Neil, C B Oliveira, X Wang, M Navarrete, A Barrera-Vargas, J Merayo-Chalico, R Aljohdali, E Aguirre-Aguilar, P Carlucci, M J Kaplan, C Carmona-Rivera

Systemic lupus erythematosus

- 639** Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
E F Morand, G Abreu, R A Furie, V Golder, R Tummala

- 646** Microglia activation in the presence of intact blood-brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupus
D Nikolopoulos, T Manolakou, A Polissidis, A Filia, G Bertias, Y Koutmani, D T Boumpas

Myositis

- 658** Role of CD14+ monocyte-derived oxidised mitochondrial DNA in the inflammatory interferon type 1 signature in juvenile dermatomyositis
M G L Wilkinson, D Moulding, T C R McDonnell, M Orford, C Wincup, J Y J Ting, G W Otto, R Restuadi, D Kellerman, C Papadopolou, S Castellano, S Eaton, C T Deakin, E C Rosser, L R Wedderburn

Systemic sclerosis

- 670** Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation
B Ayoglu, M Donato, D E Furst, L J Crofford, E Goldmuntz, L Keyes-Elstein, J James, S Macwana, M D Mayes, P McSweeney, R A Nash, K M Sullivan, B Welch, A Pinckney, R Mao, L Chung, P Khatri, P J Utz

Vasculitis

- 681** Risk factors for serious infections in ANCA-associated vasculitis
B Odler, R Riedl, P Gauckler, J I Shin, J Leierer, P A Merkel, W St. Clair, F Fervenza, D Geetha, P Monach, D Jayne, R M Smith, A Rosenkranz, U Specks, J H Stone, A Kronbichler, RAVE-ITN Research Group

MORE CONTENTS ►

Member since 2008
J.M00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics
<http://publicationethics.org/>




When you have finished with this please recycle it


This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme.
See <http://authors.bmj.com/open-access/>

Autoinflammatory disorders

- 688** Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis
 *H Gao, S Liu, Y Mai, Y Wang, X Zhang, S Zheng, C Luo, C Pan*

Epidemiology

- 698** Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
 *P M Machado, M Schäfer, S K Mahil, J Liew, L Gossec, N Dand, A Pfeil, A Strangfeld, A C Regierer, B Fautrel, C G Alonso, C G S Saad, C E M Griffiths, C Lomater, C Miceli-Richard, D Wendling, D Alpizar Rodriguez, D Wiek, E F Mateus, E Sirocich, E R Soriano, F M Ribeiro, F Omura, F Rajão Martins, H Santos, J Dau, J N Barker, J Hausmann, K L Hyrich, L Gensler, L Silva, L Jacobsohn, L Carmona, M M Pinheiro, M D Zelaya, M d l Á Severina, M Yates, M Dubreuil, M Gore-Massy, N Romeo, N Haroon, P Sufka, R Grainger, R Hasseli, S Lawson-Tovey, S Bhana, T Pham, T Olofsson, W Bautista-Molano, Z S Wallace, Z Z N Yiu, J Yazdany, P C Robinson, C H Smith*



Osteoarthritis

- 710** Human-specific duplicate CHRFAM7A gene is associated with more severe osteoarthritis and amplifies pain behaviours
A Courties, M Olmer, K Myers, P Ordoukhanian, S R Head, P Natarajan, F Berenbaum, J Sellam, M K Lotz

Images in rheumatology

- 719** Pyrogenic lower limbs
E Angeli, A A Padrón González, D Hamdan, G Pop, G Falgarone, G Bousquet

Letters

- 722** Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study
 *L Zhang, J Li, H Yin, D Chen, Y Li, L Gu, Y Fu, J Chen, Z Chen, S Yang, S Ye, T Li, L Lu*
- 724** Divergent and dominant anti-inflammatory effects of patient-derived anticitrullinated protein antibodies (ACPA) in arthritis development
 *B Raposo, M Afonso, L Israelsson, H Wähämaa, R Stålesen, F Wermeling, A H Hensvold, C Grönwall, B Rethi, L Klareskog, V Malmström*

Electronic pages

- e104** Correspondence on 'Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement'
A Z Banday, A K Jindal, S Singh
- e105** Response to: 'Correspondence on 'Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement'' by Banday *et al*
P Nash, J S Smolen
- e106** Correspondence on 'EULAR recommendations for the management of antiphospholipid syndrome in adults'
R Gao, L Qin
- e107** Response to: 'Correspondence on 'EULAR recommendations for the management of antiphospholipid syndrome in adults'' by Gao and Qin
M G Tektonidou, A Tincani, M M Ward
- e108** Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'
P Charles
- e109** Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Charles
S Ramiro, R L M Mostard, R B M Landewé
- e110** Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Charles
J S Smolen
- e111** Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'
M De Santis, A Voza, V Savevski, S Badalamenti, M Ceconi, A Mantovani, C Selmi
- e112** Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by De Santis *et al*
S Ramiro, R L M Mostard, R B M Landewé

- e113** Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry'
L Arnaud, H Devilliers
- e114** Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Arnaud and Devilliers
P M Machado, M Schäfer, A Strangfeld, L Gossec, M Gianfrancesco, S Lawson-Tovey, E F Mateus, L Carmona, K L Hyrich, P C Robinson, J Yazdany
- e115** Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry'
B Mulhearn
- e116** Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Mulhearn *et al*
M Schäfer, A Strangfeld, K L Hyrich, L Carmona, M Gianfrancesco, S Lawson-Tovey, E F Mateus, L Gossec, P C Robinson, J Yazdany, P M Machado
- e117** Comment on 'Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19' by König *et al*. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54 873 exposed individuals and 155 689 matched unexposed individuals in France
E Skidjan, L Penso, P Herlemont, J Botton, B Baricault, L Semenzato, J Drouin, A Weill, R Dray-Spira, M Zureik
- e118** Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): what does the future hold?
M Sudhakar, P Vignesh
- e119** Correspondence on 'Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis'
P Ruscitti, G Sesti, P Cipriani, R Gerli, R Giacomelli
- e120** Response to: 'Correspondence on 'Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis' by Ruscitti *et al*
J F Baker, B R England, T R Mikuls
- e121** Correspondence on 'MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group'
Z Jibri, U Gazel, D Solmaz, G Ayan, J Karsh, S Z Aydin, M Sampaio
- e122** Response to: 'Correspondence on 'MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group' by Jibri *et al*
W P Maksymowych, R GW Lambert, M Østergaard, X Baraliakos
- e123** Correspondence on 'Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment'
O N Pamuk, S Hasni
- e124** Response to: 'Correspondence on 'Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment' by Pamuk and Hasni
L Kamintsky, S D Beyea, J D Fisk, J A Hashmi, A Omisade, C Calkin, T Bardouille, C Bowen, M Quraan, A Miñitski, K Matheson, A Friedman, J G Hanly
- e125** Correspondence on 'Bowman's capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications'
S Hakroush, B Tampe
- e126** Response to: 'Correspondence on 'Bowman's capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications' by Hakroush and Tampe
V L'Imperio, G Vischini, M Ferraro, F Pagni
- e127** Correction: *The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study*